CVRX · CVRx, Inc.
Market Cap
$81.26M
Shares
26.64M
CVRX metrics
68 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$3.05
Market cap
$81.26M
Price action
19 metricsPrice change (1W)
+3.4%
Price change (30D)
+28.7%
Price change (3M)
-43.3%
Price change (6M)
-63.0%
Price change (YTD)
-57.0%
Price change (1Y)
-60.4%
Trailing year
Price change (5Y)
-83.8%
52-week high
$10.81
52-week low
$2.37
Change from 52-week high
-71.8%
Change from 52-week low
+28.7%
Annualized volatility
99.3%
Beta
0.9
RSI (14D)
41.0
Price vs SMA 50
-29.0%
Price vs SMA 200
-53.2%
Avg volume (3M)
755,464
Relative volume
1.1
Average dollar volume
$2.50M
Company
3 metricsSector
Healthcare
Industry
Medical Devices
Shares outstanding
26.64M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.3×
reciprocal yield 75.3%
P / book
4.1
reciprocal yield 24.6%
FCF yield
-50.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-64.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
1.3×
reciprocal yield 75.8%
EV / revenue historical average (5Y)
1.3×
reciprocal yield 75.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-06
Profitability
9 metricsGross margin
86.9%
Operating margin
-79.5%
Trailing 12 months
Net margin
-84.9%
Gross profit (TTM)
$53.18M
Operating profit (TTM)
−$48.64M
Net income (TTM)
−$51.97M
Trailing 12 months
Diluted EPS (TTM)
$-1.97
FCF margin
-67.1%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+15.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$61.19M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.7%
Year over year · more shares
Revenue CAGR (3Y)
+36.1%
Revenue CAGR (5Y)
+56.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-260.5%
Return on assets
-56.3%
Debt / equity
—
Current ratio
8.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$41.05M
Quick ratio
6.9
Interest coverage
-8.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$64.59M
Total assets
$92.28M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$40.46M
Capital expenditures (TTM)
$597,000
R&D (TTM)
$12.36M
SG&A (TTM)
$89.46M
Stock compensation (TTM)
$12.26M
R&D / revenue
20.2%
Stock compensation / revenue
20.0%
Ownership (13F)
3 metrics13F filers
89
13F filer change QoQ
-11
Institutional ownership
57.5%
Short interest
3 metricsShort interest
8.8%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
54 / 100
Insider activity
2 metricsNet insider buying (90D)
$73,094
Insider-sentiment score
82 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1235912
CUSIP
126638105
13F (30d)
60 filings
60 filers
Visit website
Investor relations